| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6344479 | RECORDATI RARE | Method of preventing retinopathy of prematurity in a neonate |
Mar, 2021
(3 years ago) | |
| US8415337 | RECORDATI RARE | Ibuprofen compositions and methods of making same |
Mar, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6342530 | RECORDATI RARE | Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt |
Nov, 2020
(3 years ago) | |
Neoprofen is owned by Recordati Rare.
Neoprofen contains Ibuprofen Lysine.
Neoprofen has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Neoprofen are:
- US6342530
- US6344479
Neoprofen was authorised for market use on 13 April, 2006.
Neoprofen is available in injectable;intravenous dosage forms.
Neoprofen can be used as closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500g, who are no more than 32 weeks gestational age when usual medical management is ineffective, treatment of patent ductus arteriosus.
The generics of Neoprofen are possible to be released after 02 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Apr 13, 2013 |
Drugs and Companies using IBUPROFEN LYSINE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: Treatment of patent ductus arteriosus; Closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500g, who are no more than 32 weeks gestational age w...
Dosage: INJECTABLE;INTRAVENOUS
NEOPROFEN family patents
